{"id":"alemtuzumab-i-v","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion-related reactions"},{"rate":"null","effect":"Infections"},{"rate":"null","effect":"Cytopenias"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Alemtuzumab is a monoclonal antibody that targets CD52, a protein found on mature lymphocytes. By binding to CD52, Alemtuzumab induces cell death, leading to the depletion of lymphocytes.","oneSentence":"CD52 is a surface protein on mature lymphocytes; Alemtuzumab binds to CD52 and induces cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:52:14.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia"}]},"trialDetails":[{"nctId":"NCT00951457","phase":"PHASE1, PHASE2","title":"Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2009-03","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":20},{"nctId":"NCT01186640","phase":"PHASE2","title":"Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2010-06","conditions":"T-cell-prolymphocytic Leukemia","enrollment":16},{"nctId":"NCT02411084","phase":"PHASE3","title":"Study of BEGEDINA® vs \"Conventional Treatment\" for Treating Steroid-Resistant Acute GvHD","status":"TERMINATED","sponsor":"Adienne SA","startDate":"2016-02","conditions":"Graft vs Host Disease","enrollment":36},{"nctId":"NCT00634881","phase":"PHASE1, PHASE2","title":"Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2003-11","conditions":"Chronic Lymphocytic Leukemia","enrollment":13},{"nctId":"NCT00646854","phase":"PHASE3","title":"Alemtuzumab and CHOP in T-cell Lymphoma","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2008-06","conditions":"Lymphoma, T-Cell, Peripheral","enrollment":136},{"nctId":"NCT00301834","phase":"PHASE2","title":"Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2005-01","conditions":"Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia","enrollment":35},{"nctId":"NCT00147901","phase":"PHASE2","title":"Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2005-01","conditions":"B-cell Chronic Lymphocytic Leukemia","enrollment":61},{"nctId":"NCT02694770","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Neihulizumab vs \"Conventional Treatment\" to Treat Sr-aGvHD","status":"WITHDRAWN","sponsor":"AbGenomics B.V Taiwan Branch","startDate":"2016-07","conditions":"Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation","enrollment":""},{"nctId":"NCT00316810","phase":"PHASE3","title":"Simultaneous Pancreas-kidney Transplantation With Campath Protocol","status":"COMPLETED","sponsor":"Dr. Claudia Bösmüller","startDate":"2006-04","conditions":"Pancreas-Kidney Transplantation","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Alemtuzumab i.v.","genericName":"Alemtuzumab i.v.","companyName":"German CLL Study Group","companyId":"german-cll-study-group","modality":"Biologic","firstApprovalDate":"","aiSummary":"CD52 is a surface protein on mature lymphocytes; Alemtuzumab binds to CD52 and induces cell death. Used for Chronic lymphocytic leukemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}